No registrations found.
ID
Source
Brief title
Health condition
EN: glioma
NL: glioom
Sponsors and support
Dutch Cancer Society (OAA/H1/VU 2015-7502)
Intervention
Outcome measures
Primary outcome
- Qualitative (high, normal or low signal) and quantitative parameters of MRI and PET for each biopsy site
- Qualitative (central glioma, glioma infiltration, normal brain or uninformative) histopathological score of each biopsy site
Secondary outcome
- Gene expression of each biopsy site
Study objective
1. Advanced neuroimaging, in combination with standard MRI, will have a superior diagnostic accuracy in comparison with standard MRI alone.
2. Histological and molecular characteristics of glioma will correlate better with advanced imaging than standard imaging.
Study design
Phase I (n=8) 12 months
Phase II (n=12) 12 months
Phase III (n=20) 12 months
Intervention
Observational study with PET and MRI previous to stereotactic biopsies in and around the tumor.
P.C.
de Witt Hamer
P.O. Box 7057
1007 MB
Tel: (+31) 204443783
P.C.
de Witt Hamer
P.O. Box 7057
1007 MB
Tel: (+31) 204443783
Inclusion criteria
Patients of 18 years and older with a MRI interpretation by an expert neuroradiologist of a diffuse infiltrative glioma, and who have an indication, confirmed by the multidisciplinary neuro-oncology tumor-board, for resective surgery.
Exclusion criteria
Patients who are pregnant or underwent previous brain surgery, cranial irradiation or chemotherapy. Patients with other brain pathology on MRI, such as stroke or multiple sclerosis. Patients with a tumor located infratentorially or in the spinal cord.
Withdrawal criteria
Patients who do not successfully undergo one PET scan in phase I and III or both PET scans in phase II.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL5205 |
NTR-old | NTR5354 |
Other | METC : 2013/335 |